Wojcik v. Omega Healthcare Investors, Inc.

District Court, D. Maryland·Decided August 8, 2024·No. 1:20-cv-03491·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND ROBERT WOJCIK, derivatively on behalf * of OMEGA HEALTHCARE INVESTORS, INC., * Plaintiff, * v. e CIVIL NO. JKB-20-3491 OMEGA HEALTHCARE INVESTORS, * INC., et al., * Defendants. / * * * * * * * * * * * * MEMORANDUM Pending before the Court are Plaintiff Robert Wojcik’s Motion for Final Approval of Settlement (ECF No. 85) and Motion for Final Approval of Attorneys’ Fees, Expenses, and Service Award for Plaintiff (ECF No. 86). For the reasons that follow and for the reasons explained in open court during the August 6, 2024 Hearing, the Motions are granted as detailed below. I. Background Plaintiff filed his Complaint derivatively on behalf of Omega Health Investors, Inc. (“Omega” or “the Company”) against Omega and various individual officers and directors of Omega. (See generally ECF No. 1.) Omega “is a real estate investment trust which invests in healthcare facilities, such as skilled nursing and senior care facilities” and it “either owns the properties and leases them to facility operators, or it provides operators with mortgage financing.” (ld. ¥ 2.) Plaintiff brought two categories of claims against Omega and the individual defendants, which Plaintiff refers to as the Non-Diversity Claims and the Diversity Claims. (See generally id.)

The Non-Diversity Claims relate to allegedly false or misleading statements Omega made regarding certain facility operators and Omega’s financial condition. (See id. §§ 119-215.) The Diversity Claims relate to alleged discriminatory practices. (See id. §§ 216-48.) At issue now are the Diversity Claims, as Plaintiff agreed to dismiss the Non-Diversity Claims with prejudice as to himself only.! In short, the Diversity Claims involve Omega’s failure to nominate, appoint, and/or hire Black individuals to the Board or to Omega’s executive management team (the “Discriminatory Misconduct”) and Omega’s alleged misrepresentations in its proxy statements relating to Board diversity. (ECF No. 1 § 27.) Plaintiff alleged that the individual Defendants breached their fiduciary duties by “permit[ting] the Discriminatory Misconduct, engag[ing] in and caus[ing] the Company to engage in the Discriminatory Misconduct, and fail[ing] to maintain adequate controls.” (/d. § 29.) Plaintiff also alleged that the individual Defendants “deceived investors by claiming to abide by certain antidiscrimination policies” and therefore “breached their duty of candor and [] violated the federal securities laws.” (Jd. § 30.) Plaintiff further alleged that the individual Defendants “caused the Company to violate Section 14(a) of the Exchange Act” because

' As Plaintiff explains: In making his Non-Diversity Claims, Plaintiff also alleges that, between February 8, 2017 and October 31, 2017, the Individual Defendants made and/or caused Omega to make false and misleading statements and omissions of material fact about, inter alia, the financial and operating results and liquidity of the Company’s operators and the resulting impairment of the Company’s direct finance leases. The same or substantially similar statements were also alleged to be false and misleading: (1) in a consolidated securities fraud class action captioned /n re: Omega Healthcare Investors, Inc. Securities Litigation, Case No. 1:17-cv-08983 (S.D.N.Y.) (the “Securities Class Action”); (2) in a shareholder derivative suit brought on behalf of Omega captioned Stourbridge Investments, LLC v. Callen et al., Case No. 1:18-cv-07638 (S.D.N.Y.) (the “Stourbridge Action’); and (3) in a consolidated shareholder derivative suit brought on behalf of Omega captioned Swan v. Pickett et al., Case No. 24-C-19-000972 (Balt. Cit. Cir. Ct. Md.) (the “Swan Action,” and together with the Stourbridge Action, the “Other Derivative Actions”). (ECF No. 85-1 at 11 n.5.) Plaintiff states that these other actions have been resolved through separate settlements. (id. at 7 n.2.)

Omega’s proxy statements were false and misleading because, inter alia, they failed to disclose that: (1) Omega had engaged in discriminatory practices; (2) Omega did not have term limits due to a desire to keep Black individuals off of the Board; (3) Omega’s Nominating and Corporate Governance Committee did not actually consider racial diversity when nominating Board candidates; and (4) Omega failed to maintain adequate internal controls. (/d. § 32.) As relief, Plaintiff sought damages and various corporate governance reforms. (Jd. at 117-18.) Plaintiff filed his Complaint in December 2020, and the parties thereafter agreed to stay the case pending the outcome of related litigation (ECF Nos. 36, 37). The parties provided periodic Status reports. (See ECF Nos. 46, 51, 57, 59, 61, 64, 66, 68, 70, 72, 74.) The parties to this matter and to the other related matters described above engaged the services of a mediator in December 2020. (ECF No. 77-4 at 3.) On December 31, 2020, the parties exchanged mediation briefs, and Plaintiff's settlement demand included a corporate governance reform proposal and damage analysis. (/d. at 4.) In January 2021, the parties to this matter and to the other related matters participated in an all-day mediation session with the mediator, and thereafter conducted negotiations over the next 19 months. (Id.) In September 2022, the parties to this matter and to the other related matters participated in another all-day mediation session, which resulted in the resolution of the Securities Class Action, but not of this matter or the Other Derivative Actions. (/d.) The parties continued their discussions, and ultimately agreed in September 2023 on the material terms of a settlement. (/d.) Pursuant to the proposed settlement agreement with respect to this matter, Omega’s Board of Directors agreed to adopt and to maintain for at least two years a series of corporate governance reforms: (a) the appointment of a new independent and diverse director to the Board; (b) the creation of an Environmental, Social, and Governance (“ESG”) Steering

Free access — add to your briefcase to read the full text and ask questions with AI

Wojcik v. Omega Healthcare Investors, Inc., (D. Md. 2024).

Wojcik v. Omega Healthcare Investors, Inc. (Wojcik v. Omega Healthcare Investors, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Mills v. Electric Auto-Lite Co.
396 U.S. 375 (Supreme Court, 1970)
Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Zimmerman v. Bell
800 F.2d 386 (Fourth Circuit, 1986)
Cohn v. Nelson
375 F. Supp. 2d 844 (E.D. Missouri, 2005)
Eileen McAfee v. Christine Boczar
738 F.3d 81 (Fourth Circuit, 2013)
Gregory Berry v. LexisNexis Risk and Information
807 F.3d 600 (Fourth Circuit, 2015)
Teresa Speaks v. U. S. Tobacco Cooperative Inc.
917 F.3d 276 (Fourth Circuit, 2019)
In re Fab Universal Corp. Shareholder Derivative Litigation
148 F. Supp. 3d 277 (S.D. New York, 2015)
Ingram v. Coca-Cola Co.
200 F.R.D. 685 (N.D. Georgia, 2001)
Johnson v. Georgia Highway Express, Inc.
488 F.2d 714 (Fifth Circuit, 1974)